Krystal Biotech, Inc.

Stage 3 · Topping · week 5

As of Oct 22, 2026, Krystal Biotech is in Stage 3, the topping phase, now in week 5 (since Sep 21, 2026). It closed at $320.13, 15.3% below its 52-week high and above its 200-day average, which is rising.

$320.13

-0.63% today

$9.5B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is KRYS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S3 13w

S2 19w

S2 24w

S2 19w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 6w → S3 13w → S2 2w → S1 1w → S2 19w → S3 5w → S2 13w → S3 12w → S4 12w → S1 8w → S4 12w → S1 10w → S2 24w → S3 6w → S2 19w → S3 5w current

Total tracked: 164 weeks across 16 stage runs.

KRYS among Biotechnology71st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…71	KRYSKrystal Biotech, Inc.	Stage 3 · wk 5	91	−6.3%

vs 52W High

-15.3%

$185.05 lo$378.15 hi

15.3% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 5

1w13w26w

Week 5, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

4.3%

200 DMA: $306.97 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.94x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-6.3%

-4.5%

+19.4%

YTD

+29.7%

+67.8%

Scan Membership

Breakout Watch

Latest: 2024-07-02

13 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 5 · Vol 0.94x

2026-10-21S3

Wk 5 · Vol 1.59x

2026-10-20S3

Wk 5 · Vol 0.77x

2026-10-19S3

Wk 5 · Vol 0.82x

2026-10-16S3

Wk 4 · Vol 0.90x

2026-10-15S3

Wk 4 · Vol 1.14x

2026-10-14S3

Wk 4 · Vol 1.07x

2026-10-13S3

Wk 4 · Vol 1.02x

2026-10-12S3

Wk 4 · Vol 0.59x

2026-10-09S3

Wk 3 · Vol 0.69x

2026-10-08S3

Wk 3 · Vol 0.95x

2026-10-07S3

Wk 3 · Vol 1.23x

Moving averages & range

50 DMA

$339.17

200 DMA

$306.97

52W High

$378.15

52W Low

$185.05

5D Low

$316.58

Resistance levels (recent highs)

20d High

$345.82

60d High

$371.47

120d High

$378.15

250d High

$378.15

Next resistance

+8.0%

to 20d High

P/E (TTM)

40.1

Forward 35.8

Earnings Growth (YoY)

+38.8%

Revenue +24.1%

ROE

+20.1%

Profit margin +54.8%

Dividend Yield

0.00%

P/B 7.0

Krystal Biotech: quick answers

What stage is Krystal Biotech in?

As of Oct 22, 2026, Krystal Biotech (KRYS) is in Stage 3, the topping phase. It entered Stage 3 on Sep 21, 2026 and is in week 5. What the four stages mean

Is Krystal Biotech in an uptrend?

Its uptrend has stalled. Krystal Biotech is in Stage 3, the topping phase that follows an advance. It trades 4.3% above its 200-day average, which is rising.

How far is Krystal Biotech from its 52-week high?

Krystal Biotech closed at $320.13 on Oct 22, 2026, 15.3% below its 52-week high of $378.15. Its 52-week low is $185.05.

How has Krystal Biotech performed over the past year?

As of Oct 22, 2026, Krystal Biotech is up 67.8% over the past year and up 29.7% so far in 2026.

Which sector and industry is Krystal Biotech in?

Krystal Biotech is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.